Avistone

Beijing Avistone Biotechnology Co., Ltd. is a commercial-stage innovative biopharmaceutical company headquartered in Beijing, China, focused on the research, development, and commercialization of first-in-class and best-in-class oncology therapies. Founded in 2012 (originally Beijing Pearl Biotechnology) and renamed Avistone in 2018, the company has two approved cancer drugs on the market: Vebreltinib (万比锐®), a MET inhibitor approved for non-small cell lung cancer and glioma indications and included in China's National Reimbursement Drug List, and Andamertinib (安比锐®), an EGFR exon 20 insertion inhibitor approved in 2026 for advanced NSCLC. Avistone maintains a pipeline of additional candidates (ANS01 through ANS09) across solid-tumor indications and is backed by IDG Capital. The company publishes no public developer API or programmatic surface; this profile captures its corporate and investor identity.

Avistone is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biopharmaceutical, Oncology, and Pharmaceuticals.

🌐 Visit website 📡 Source on GitHub

8.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealthcareBiopharmaceuticalOncologyPharmaceuticalsDrug DevelopmentBiotechnologyCancer TherapeuticsChina

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 8.8/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/avistone: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 4

The organization behind the API

Website

Website

Website

Website

Careers

Careers

InvestorRelations

InvestorRelations

Source (apis.yml)

aid: avistone
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/avistone.png
name: Avistone
description: 'Beijing Avistone Biotechnology Co., Ltd. is a commercial-stage innovative biopharmaceutical company headquartered
  in Beijing, China, focused on the research, development, and commercialization of first-in-class and best-in-class oncology
  therapies. Founded in 2012 (originally Beijing Pearl Biotechnology) and renamed Avistone in 2018, the company has two approved
  cancer drugs on the market: Vebreltinib (万比锐®), a MET inhibitor approved for non-small cell lung cancer and glioma indications
  and included in China''s National Reimbursement Drug List, and Andamertinib (安比锐®), an EGFR exon 20 insertion inhibitor
  approved in 2026 for advanced NSCLC. Avistone maintains a pipeline of additional candidates (ANS01 through ANS09) across
  solid-tumor indications and is backed by IDG Capital. The company publishes no public developer API or programmatic surface;
  this profile captures its corporate and investor identity.'
url: https://raw.githubusercontent.com/api-evangelist/avistone/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- idg-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Healthcare
- Biopharmaceutical
- Oncology
- Pharmaceuticals
- Drug Development
- Biotechnology
- Cancer Therapeutics
- China
apis: []
common:
- type: Website
  url: https://en.avistonebio.com
- type: Website
  url: https://www.avistonebio.com
- type: PrivacyPolicy
  url: https://www.avistonebio.com/privacy_policy.html
- type: Careers
  url: https://www.avistonebio.com/join_index.html
- type: InvestorRelations
  url: https://www.avistonebio.com/investor_index.html
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence